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The neuronal long isoform of Fas Apoptotic InhibitoryMolecule (FAIM-L) protects from death receptor (DR)-induced apoptosis, yet its
mechanism of protection remains unknown. Here, we show that FAIM-L protects rat neuronal Type II cells from Fas-induced apoptosis.
XIAPhaspreviously emergedasamoleculardiscriminator that isupregulated inType II anddownregulated inType I apoptotic signaling.
We demonstrate that FAIM-L requires sustained endogenous levels of XIAP to protect Type II cells as well as murine cortical neurons
from Fas-induced apoptosis. FAIM-L interacts with the BIR2 domain of XIAP through an IAP-binding motif, the mutation of which
impairs the antiapoptotic function of FAIM-L. Finally, we report that FAIM-L inhibits XIAP auto-ubiquitinylation and maintains its
stability, thus conferring protection from apoptosis. Our results bring new understanding of the regulation of endogenous XIAP by a DR
antagonist, pointing out at FAIM-L as a promising therapeutic tool for protection from apoptosis in pathological situations where XIAP
levels are decreased.
Introduction
Appropriate control of death receptor (DR)-induced caspase ac-
tivation is essential for neuronal survival (Choi and Benveniste,
2004). The activation of DRs induces the formation of the death-
inducing signaling complex (DISC), thereby triggering apoptosis
(Wilson et al., 2009). Activation of Fas DR either leads to direct
caspase-3 activation in Type I cells or implicates the mitochon-
dria through caspase-8-mediated cleavage of Bid in Type II cells
(Scaffidi et al., 1998).
Antiapoptotic members of the Bcl-2 family play an important
and early role in neuronal protection from apoptosis (Motoyama
et al., 1995; Michaelidis et al., 1996; Berman et al., 2009). Inhib-
itors of apoptosis proteins (IAPs) also protect fromDRactivation
and contain three baculovirus inhibitory repeat (BIR) domains,
a UBA domain that binds to poly-ubiquitin chains, and a
C-terminal Really Interesting New Gene (RING) domain that
bears an E3-ligase activity (Darding andMeier, 2012). XIAP is the
most potent caspase inhibitor in vitro (Eckelman and Salvesen,
2006; Srinivasula and Ashwell, 2008) and plays an important role
in preventing Fas-induced apoptosis in hepatocytes (Jost et al.,
2009; Ferreira et al., 2012). XIAP BIR2 domain binds to and
inhibits caspase-3 and caspase-7 (Riedl et al., 2001; Silke et al.,
2001; Scott et al., 2005), whereas XIAP BIR3 domain binds
caspase-9 (Shiozaki et al., 2003). Also, XIAP undergoes auto-
ubiquitinylation and proteasome-mediated degradation in
response to apoptotic stimuli (Yang et al., 2000). XIAP deregula-
tion has been shown extensively in peripheral nervous system-
related diseases (Garrity-Moses et al., 2006).
A group of proteins designated DR antagonists have been de-
scribed and are promising for the protection from neuronal cell
death: c-FLIP (Irmler et al., 1997), NMP35/Lifeguard/FAIM2
(Somia et al., 1999; Ferna´ndez et al., 2007), and Fas Apoptotic
InhibitoryMolecule (FAIM) (Schneider et al., 1999; Zhong et al.,
2001). Nevertheless, with the exception of c-FLIP (Taoufik et al.,
2007; Moubarak et al., 2010), the mechanism of action of other
DR antagonists and their relevance in the nervous system remain
to be clarified.
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FAIM is a DR antagonist with two isoforms that display very
diverse roles in the nervous system. We have reported that the
short form FAIM-S is necessary for neurite outgrowth through
the activation of the MAPK/ERK and NF-B pathways (Sole et
al., 2004).Whereas FAIM-S is ubiquitous and protects B lympho-
cytes but not neurons from Fas activation, the long form FAIM-L
is exclusively expressed in neurons and protects them from
DR activation (Segura et al., 2007). FAIM-L also controls Fas-
induced apoptosis in midbrain dopaminergic neurons after
trophic factor deprivation (Yu et al., 2008), underlining the po-
tential interest of FAIM-L for neuroprotection in models of Par-
kinson disease. However, the detailed molecular mechanism
through which FAIM-L protects from DR-induced apoptosis is
currently unknown.
Here, we provide compelling evidence that FAIM-L interacts
with XIAP through an IAP-binding motif (IBM) in the N termi-
nus of FAIM-L, thereby impairing XIAP auto-ubiquitinylation
and degradation by the proteasome. In addition, we demonstrate
that, upon Fas activation, sustainedXIAP protein levels are essential
for FAIM-L-mediated protection fromapoptosis.Our findings pro-
vide the first evidence of a neuron-specific molecule that is able to
regulate XIAP auto-ubiquitinylation and degradation.
Materials andMethods
Reagents. Recombinant human sFasL (superFasL, Enzo Life Sciences)
was used at a concentration of 100 ng/ml. Fluorogenic caspase substrate
Ac-DEVD-afc was purchased from Calbiochem/Merck Biosciences. Un-
less otherwise specified, all biochemical reagents were purchased from
Sigma-Aldrich.
Cell culture.Rat pheochromocytomaPC12 cells were grownon culture
plates coated with Type I collagen (66.4 g/ml; BD Biosciences) in
DMEM supplemented with 6% heat-inactivated fetal bovine serum
(FBS) and 6%heat-inactivated horse serum (Invitrogen), 10mMHEPES,
20 U/ml penicillin, and 20 g/ml streptomycin. HEK293T and HEK293
cells were grown in DMEM supplemented with 10% heat-inactivated
FBS (Invitrogen), 20 U/ml penicillin, and 20 g/ml streptomycin. Cul-
turesweremaintained at 37°C in a humidified atmosphere of 95%air and
5% CO2.
Primary cortical neurons culture. Female C57BL/6mice were killed and
manipulated following the experimental protocol approved by the Vall
d’Hebron Institutional Review Board. Embryonic cerebral cortices were
dissected from mouse embryos at day 16 (E16). Cells were counted and
resuspended in DMEM with glutamine supplemented with 5% heat-
inactivated FBS and 5% heat-inactivated fetal horse serum, 20 U/ml
penicillin, and 20 g/ml streptomycin. Cells were plated in 25 mg/ml
poly-L-lysine-coated plates at a density of 1.6 105 cells/cm2. Transduc-
tion with short hairpin lentiviruses was performed while seeding. Four
hours after seeding and transduction, the medium was replaced with
serum-free Neurobasal medium supplemented with 2% B27 (Invitro-
gen), 1% N2 (Invitrogen), 20 U/ml penicillin, 20 g/ml streptomycin,
and 0.5 mM glutamine. Culture medium was partially replaced every
3–4 d with fresh Neurobasal supplementedmedium.When indicated,
subsequent transductions were performed 3 d after prior transduc-
tion. Cell culture plates were kept at 37°C in a humidified incubator
with 5%CO2/95%air.
Plasmids. Fas, 3xHA-c-FLIP-L, 3xHA-Bcl-xL, 6xMyc-XIAP, 3xFLAG-
FAIM-L, and 3xHA-FAIM-L cDNAswere expressed under the control of
a cytomegalovirus constitutive promoter in the pcDNA3 expression vec-
tor (Invitrogen). The 6xHis-tagged ubiquitin plasmid, pMT107, was a
kind gift fromDr. Dirk Bohmann (University of RochesterMedical Cen-
ter) (Treier et al., 1994). The C-terminal FLAG-tagged XIAP (wild-type,
deletion, and point mutants) cloned in the pEF plasmid was a kind gift
from Dr. John Silke (Walter and Eliza Institute, Melbourne, Australia)
and were described by Silke et al. (2002).
For RNA interference (RNAi) experiments, constructs were generated in
the pSUPER.retro.puro plasmid (OligoEngine) using specific oligonucleo-
tides against rat XIAP (sequence data available from GeneBank under
accession number NM_022231) indicated by capital letters, as follows:
shXIAP R1, forward, gatccccAGAATCCTATGGTGCAAGAttcaagagaTCT
TGCACCATAGGATTCtttttt;
reverse, agctaaaaaAGAATCCTATGGTGCAAGAtctcttgaaTCTTG-
CACCATAGGATTCggg; or
shXIAP R2, forward, gatccccGTAGATAGATGGCAGTATGttcaagaga
CATACTGCCATCTATCTACtttttt;
reverse, agctaaaaaGTAGATAGATGGCAGTATGtctcttgaaCATACT-
GCCATCTATCTACggg. A scrambled sequence was used as a control by
the following oligonucleotides: Scr, forward, gatccccAGAACACGACG-
GAACAAGAttcaagagaTCTTGTTCCGTCGTGTTCTttttt; reverse, agcta
aaaaAGAACACGACGGAACAAGAtctcttgaaTCTTGTTCCGTCGTG
TTCTggg. Oligonucleotides were obtained from Sigma and were cloned
between BglII/HindIII sites of pSUPER.retro.puro plasmid. Lentiviral
constructs were achieved by digesting EcoR1-ClaI sites from pSUPER-sh
to replace H1 promoter with H1-shRNA cassette in pLVTHM plasmid.
For FAIM-L knockdown experiments, we used the lentiviral plasmid
pLVTHM-shFAIM-L, which targets specifically the long form and not
the short form of FAIM and has been previously validated by Segura et al.
(2007).
Site-directed mutagenesis. The XIAP E3-ubiquitin ligase mutant
H467A previously described (Yang et al., 2000) has been cloned in by
site-directed mutagenesis in the pcDNA3–6xMyc-XIAP plasmid using
the PfuI polymerase PCR (Stratagene) and the following primers carry-
ing the mutation and a SacI recognition site for cribling of positive
colonies: forward, 5-TATCGTTTTTGTTCCTTGTGGAGCTCTAGT
CACTT-3; reverse, 5-AAGTGACTAGAGCTCCACAAGGAACAAA
AACGATA-3. The FAIM-L mutant (MutFAIM-L) where the first ala-
nine was replaced by a glycine was cloned using the same protocol
and the following primers carrying the mutation and a BamHI recog-
nition site for cribling of positive colonies: forward, 5-ACCGAATTCA
TGGGATCCGGAGAT-3; reverse, 5-ATCTCCGGATCCCATGAA
TTCGGT-3. All constructs were verified by digestion and sequencing.
Lentiviral production. Lentiviruses were produced as described previ-
ously by Segura et al. (2007).
Cell transfection and infection.HEK293 or PC12 cells were transfected
with the desired expression plasmid using Lipofectamine 2000 (Invitro-
gen), following the manufacturer’s instructions. HEK293T were trans-
fected using the calcium phosphate method. The total amount of
transfected DNA was kept constant in all experiments by adding empty
vector.
For lentiviral-based knockdown experiments, PC12 cells were seeded
in 24-multiwell plates at a density of 2 104 cells/well. Titrated lentivi-
ruses were added to themedium. After 4 h, themediumwas changed and
the transduction efficiency monitored by direct counting of GFP-
positive cells. The percentage of infection reached 95%. Lentiviruses ef-
ficiently induced XIAP or FAIM-L knockdown after 3 d of transduction.
Knockdown efficiency was checked by RT-PCR or Western blotting,
respectively, prior cell death induction.
RT-PCR. A total of 1 g of total RNA was converted to first-strand
cDNA using the MLV Reverse Transcriptase (Promega Biotech). The
resulting cDNA was subjected to PCR analysis. PCR cycling parameters
were as follows: 94°C for 2 min for one cycle, followed by 94°C for 30 s,
60°C for 30 s, and 72°C for 60 s for 30 cycles; 72°C for 5minwith xiap and
the housekeeping ribosomal protein L27 primers. The PCR products
were run on an agarose gel that was stained with SYBR Safe (Invitrogen).
The sequences of specific primers are as follows: xiap, forward, 5-
TGAAGAAGCCAGACCGAAGA-3; reverse, 5-TGACTTGACTCATC-
CTGCGA-3; and L27, forward, 5-AGCTGTCATCGTGAAGAA-3;
reverse, 5-CTTGGCGATCTTCTTCTTGCC-3.
Cytochrome c and Smac release from the mitochondria. Cytosolic puri-
fication was performed as previously described (Moubarak et al., 2007).
Briefly, 2 106 PC12 cells were resuspended in a buffer containing 220
mM mannitol, 70 mM sucrose, 50 mM HEPES-KOH, pH 7.2, 10 mM KCl,
5 mM EGTA, 2 mM MgCl2, and 0.025% digitonin, and kept on ice for 5
min. Lysed cells were centrifuged (16,000  g; 5 min; 4°C), and the
supernatant was retained as the cytosolic fraction. The release of cyto-
chrome c and Smac from themitochondria to the cytosol was assessed by
Western blot.
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Western blot. Cells were harvested and rinsed once with ice-cold PBS
1, pH 7.2 and, unless otherwise indicated, lysed in immunoprecipita-
tion lysis buffer (20 mM Tris, pH 7.4, 140 mM NaCl, 10% glycerol, 2 mM
EDTA, 1 mM EGTA, 1% Igepal CA-630), supplemented with 1 EDTA-
free Complete protease inhibitor mixture (Roche), before centrifugation
at 16 000  g, 4°C and harvesting supernatants. Protein concentration
was quantified by a modified Lowry assay (DC protein assay; Bio-Rad).
The cell lysates obtained were resolved by SDS-PAGE and transferred
onto PVDF Immobilon-P membranes (Millipore). After blocking with
TBS 1-0.1% Tween-20 containing 5% nonfat dry milk for 1 h at room
temperature, membranes were probed with the appropriate primary
antibodies, before incubation for 1 h with the appropriate specific
peroxidase-conjugated secondary antibody.Membranes were developed
using the EZ-ECL chemiluminescence detection kit (Biological Indus-
tries) or SuperSignal Dura (Pierce/Thermo Fisher Scientific). The pri-
mary antibodies used were the following: anti-XIAP (BD Biosciences),
anti-FAIM-L (in house), anti-tubulin (Sigma), anti-Bcl-xL and anti-
cytochrome c (BD Biosciences), anti-HA (Roche), anti-Smac (Prosci),
anti-Fas (Santa Cruz Biotechnology), anti-caspase-8, anti-rat or anti-
human caspase-9, anti-caspase-3, and anti-PARP (Cell Signaling Tech-
nology). In some cases, equal loading was verified by Naphtol Blue
staining of the PVDF membrane.
Immunoprecipitation. Samples were lysed in immunoprecipitation ly-
sis buffer as described above and lysates were quantified by a modified
Lowry assay (DC protein assay; Bio-Rad). A total of 1 mg of total protein
was adjusted with immunoprecipitation buffer to achieve a concentra-
tion of 1 mg/ml. A total of 40 l of anti-FLAG M2-agarose-coupled
antibodywere added to each sample and incubated overnight at 4°C in an
orbital shaker. Then, beads were washed five times with immunoprecipi-
tation buffer and eluted for 30 min at 4°C with 80 l of TBS1 contain-
ing 150 ng/ml of 3xFLAG competitor peptide. After a short spin,
supernatants were carefully taken, Laemmli buffer was added, and SDS-
PAGE was performed. Alternatively, for semiendogenous and endoge-
nous immunoprecipitations, 1 mg of cleared supernatant from PC12
cells was subjected to immunoprecipitation with 10 l of an anti-
FAIM-L antibody or a control rabbit IgG, such as the anti-Myc antibody
(Santa Cruz Biotechnology) overnight at 4°C. Immunocomplexes were
collected with protein G-Sepharose by orbital shaking for overnight at
4°C and washed five times with immunoprecipitation lysis buffer. Beads
were suspended in Laemmli buffer and boiled; then samples were re-
solved by SDS-PAGE. For Western blot of endogenous immunoprecipi-
tation, the secondary anti-rabbit used was purchased from eBioscience.
Detection of Bax conformational change by immunoprecipitation. PC12
cells were transfected with the indicated plasmids and then treated 48 h
after transfection as indicated. At the end of the incubation, cells were
harvested, washed once with PBS, and lysed in 1ml of lysis buffer (10mM
HEPES, pH 7.4, 125 mMNaCl, and 1%CHAPS), supplemented with 1
EDTA-free Complete protease inhibitor mixture (Roche) and incubated
for 30 min on ice. Cells were then subjected to 3 freeze-and-thaw cycles
(dry ice and ethanol for 3 min, 37°C for 3 min, and vortex for 15 s) and
centrifuged at 16,000  g for 1 h at 4°C. Protein concentration of the
supernatants was measured with the modified Lowry assay, and aliquots
of 500 g of each sample were brought to a volume of 500 l with lysis
buffer. Samples were incubated with 25l of protein G agarose beads for
1 h at 4°C to reduce the nonspecific binding to the beads and were
subsequently spun down at 12,000  g for 1 min to remove the beads.
The supernatants were incubated with 2g of the conformation-specific
anti-Bax monoclonal antibody (clone 6A7; BD Biosciences) for 2 h at
4°C, and then 25 l of protein G agarose beads were added to the reac-
tions and incubated at 4°C for an additional hour. Beads were recovered
after short spinning, washed 6 times with lysis buffer, and boiled in 25l
of Laemmli buffer 2. The samples were loaded on 14% acrylamide gels
and analyzed by immunoblot using a rabbit polyclonal anti-Bax antibody
(Millipore) as primary antibody.
Cell viability assays. For apoptotic nuclear morphology, cells were
plated in 24-well plates and treated as indicated. Cells were then fixed
with 2% paraformaldehyde and stained with 0.05 g/ml of Hoechst
33258 for 30 min at room temperature, in a buffer composed of 2%
paraformaldehyde and 1% of Igepal CA-630. Condensed or fragmented
nuclei were counted as dead cells as described previously (Yuste et al.,
2001). The quantification of cell death by chromatin condensation was
performed in blind testing, counting at least 300 cells for each data point,
and was repeated at least three times in independent experiments.
Caspase activity. After the indicated treatments, cells were rinsed once
with PBS and resuspended in lysis buffer containing 20 mM HEPES/
NaOH, pH 7.2, 10% sucrose, 150 mM NaCl, 10 mM DTT, 5 mM EDTA,
1% Igepal CA-630, 0.1%CHAPS, and 1 EDTA-free Complete protease
inhibitor mixture (Roche). Lysates were cleared by centrifugation at 16
000  g for 5 min, and supernatants were quantified by the Bradford
method (Bio-Rad). Assays were performed in triplicate using 25 g of
protein in the same specific lysis buffer supplemented with 25 M of the
fluorogenic substrate Ac-DEVD-afc. Plates were read in a fluorimeter
using a 360 nm (40 nmbandwidth) excitation filter and a 530 nm (25 nm
bandwidth) emission filter.
Detection of ubiquitinylated proteins. Ubiquitinylated proteins were
detected using the 6xHis-ubiquitin assay for mammalian cell protocol of
the Tansey laboratory (www.tanseylab.com). HEK293T cells were trans-
fected with the plasmid(s) of interest, along with the plasmid pMT107,
which encodes 6xHis-tagged human ubiquitin. Cells were harvested 48 h
after transfection using ice-cold PBS 1. A small fraction of each condi-
tion was lysed in Laemmli buffer 2 and boiled at 95°C for 10 min and
was later loaded by SDS-PAGE as lysates. The rest of the samples were
lysed in buffer A (6 M guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4, 10 mM
imidazole, pH 8.0) and sonicated. Then His-tagged proteins were puri-
fied using Ni-NTA-agarose (Invitrogen), by rotation using an orbital
shaker for 3 h at room temperature. Samples were spun andwashed twice
with buffer A, twice in buffer A/TI (1 volume of buffer A for 3 volumes of
buffer TI), and once more in buffer TI (25 mM Tris-HCl, 20 mM imida-
zole, pH 6.8) before elution in 100 l of Laemmli buffer 2 supple-
mented with 250 mM imidazole and boiling for 10 min at 95°C.
Pre- (Lysates) and post- (His purification), Ni-NTA-agarose samples
were analyzed by SDS-PAGE/Western blotting.
Statistical analysis. All the experiments were repeated at least three
times. Values are expressed as mean SD.
Results
FAIM-L protects Type II but not Type I cells from
DR-induced apoptosis
To characterize FAIM-L mechanism of protection from apopto-
sis, we first overexpressed this protein in PC12 and HEK293 cells
in parallel with two other antiapoptotic proteins. Bcl-xL is an
antiapoptotic member of the Bcl-2 family that inhibits the death
signal at the level of the mitochondria (Youle and Strasser, 2008)
and has been used as the definitive tool to classify DR-induced
apoptosis as Type I, which cannot be prevented by Bcl-xL over-
expression, or Type II, which can be prevented by Bcl-xL overex-
pression. c-FLIP-L is a DR antagonist that competes with
caspase-8 for its recruitment to the DISC after DR engagement
(Lavrik and Krammer, 2012). As shown in Figure 1A, PC12 cells
were sensitive to FasL-induced apoptosis, but only when de novo
protein synthesis has been blocked byActinomycinD (AD). After
24 h of treatment, the overexpression of Bcl-xL, FAIM-L, and
c-FLIP-L was able to significantly inhibit sFasL plus AD-induced
apoptosis (Fig. 1A). Efficiency of overexpression was checked by
Western blot (data not shown). The protective effect of Bcl-xL
supports that PC12 cells behave as Type II cells in response to
Fas-induced apoptosis. When HEK293 cells were treated with
sFasL, only c-FLIP-L, but not Bcl-xL or FAIM-L, was able to
protect from sFasL or sFasL and AD treatment (Fig. 1B). There-
fore, HEK293 cells respond as Type I to sFasL treatment, where
activation of effector caspases by sFasL-induced activation of
caspase-8 is sufficient for cell death. To explore the differences
in FAIM-L protection between Type II and Type I cells, we
compared the processing of caspases and their substrate
poly(ADP-ribose) polymerase (PARP) inPC12 andHEK293 cells
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overexpressing Bcl-xL or FAIM-L. PC12 cells were treated with a
combination of sFasL and AD (Fig. 1C), whereas sFasL treatment
alone was sufficient for killing HEK293 cells in shorter time
points (Fig. 1D). As shown in Figure 1C, the cleavage of PARP is
inhibited by Bcl-xL and FAIM-L overexpression in the first 24 h
of treatment, compared with pcDNA3-transfected cells where
PARP is cleaved as soon as 12 h after treatment. PARP is cleaved
in Bcl-xL and FAIM-L-overexpressing cells after 48 h of treat-
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Figure 1. FAIM-L protects Type II but not Type I cells from Fas ligand-induced apoptosis. A, PC12 cells were transfected with pcDNA3, 3xHA-Bcl-xL, 3xFLAG-FAIM-L, or 3xHA-c-FLIP-L expression
plasmids and treatedwith sFasL (100 ng/ml) and AD (1 nM) for 24 h. The percentage of apoptotic cells was assessed by counting nuclei with apoptoticmorphology.B, HEK293 cells were transfected
and treated as inA for 8 h, and the percentage of apoptotic cells was determined. C, PC12 cells were transfectedwith pcDNA3, 3xHA-Bcl-xL, or 3xFLAG-FAIM-L expression plasmids and treatedwith
sFasL and AD. Cleavage of caspases and their substrate PARP was assessed byWestern blot. D, HEK293 cells were transfected and treated with sFasL prior Western blot analysis as in C. E, DEVDase
activitywasmeasured in PC12 cells thatwere treatedwith sFasL andAD for 24h.F, DEVDase activitywasmeasured inHEK293 cells thatwere treatedwith sFasL for 8 h. Error bars indicate SD. Student
test was performed, comparing transfected cells treated with sFasL or sFasLAD with their pcDNA3-transfected counterpart. * p 0.01. **p 0.001.
Moubarak et al. • FAIM-L Regulates XIAP Stability J. Neurosci., December 4, 2013 • 33(49):19262–19275 • 19265
ment, when apoptosis is no longer inhibited. However, cleavage
of caspase-9 and caspase-3 is totally inhibited by Bcl-xL but only
partially by FAIM-L overexpression, suggesting that caspases are
cleaved but not active in FAIM-L-overexpressing cells. On the
other hand, neither Bcl-xL nor FAIM-L overexpression inhibited
PARPor caspases-8, -9, and -3 inHEK293 cells treatedwith sFasL
between 2 and 8 h (Fig. 1D). In accordance with these results,
when DEVDase activity was measured by a fluorometric assay,
the activation of effector caspases was significantly inhibited by
Bcl-xL and FAIM-L overexpression in Type II PC12 cells (Fig.
1E), but not Type I HEK293 cells (Fig. 1F). These data demon-
strate that FAIM-L and Bcl-xL are able to protect Type II but not
Type I cells from Fas-induced apoptosis.
Both XIAP and FAIM-L protect PC12 cells from FasL-induced
apoptosis downstream Bax activation
It is unclear why FAIM-L protects Type II but not Type I cells
from DR-induced apoptosis. To gain further understanding of
this protection mechanism, we postulated that XIAP, a molecule
that has recently emerged as a discriminator between Type I and
Type II apoptosis induced by Fas (Jost et al., 2009; Varfolomeev et
al., 2009), might be differentially regulated in PC12 and HEK293
cells. Indeed, even though basal levels of XIAP are somehow sim-
ilar in both cells lines, XIAP protein levels were upregulated in
PC12 cells as soon as 2 h after sFasL and AD treatment (Fig. 2A)
and downregulated in HEK293 cells after 4 h of sFasL treatment.
As reported previously in other cellular models (Deveraux et al.,
1999; Conte et al., 2001), apoptosis induced by sFasL and AD
treatment in PC12 cells was significantly inhibited by XIAP over-
expression, at the same extent as FAIM-L overexpression (Fig.
2C). XIAP antagonizes cell death downstream of mitochondrial
engagement by sequestration and inhibition of caspase-3 and
processed caspase-9. To determine whether FAIM-L acts up-
stream or downstream mitochondrial engagement, we assessed
Bax activation by immunoprecipitation of active Bax in PC12
cells transfected with Bcl-xL, XIAP, or FAIM-L and treated with
sFasL and AD for 24 h. Even though all three antiapoptotic pro-
teins efficiently inhibited FasL-induced apoptosis, only Bcl-xL
overexpression prevented Bax activation. Subsequently, we as-
sessedwhether these antiapoptotic proteins are able to inhibit the
release of proapoptotic factors from the mitochondrial inter-
membrane space. Whereas Bcl-xL overexpression impairs both
cytochrome c and Smac release from the mitochondria, neither
XIAP nor FAIM-L is able to do so (Fig. 2E). Therefore, since
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neither Bax activation nor cytochrome c/Smac release is pre-
vented compared with pcDNA3-transfected cells (Fig. 2D,E), we
conclude that both XIAP and FAIM-L exert their antiapoptotic
role downstream mitochondrial engagement.
Endogenous XIAP is essential for protection by FAIM-L
Our findings that FAIM-L can only protect Type II cells where
XIAP is upregulated after FasL treatment strongly suggest that
FAIM-L might require sustained endogenous XIAP to exert its
antiapoptotic function. To support this hypothesis, we per-
formed knockdown experiments in PC12 cells using two differ-
ent shRNA-targeting XIAPs (XIAP R1 and R2) (Fig. 3A), or
FAIM-L shRNA that specifically targets FAIM-L but not FAIM-S
(Segura et al., 2007) (Fig. 3B). Three days after cell transduction
with lentiviral particles carrying Scrambled (Scr), XIAP shRNA
R1 or R2, or FAIM-L shRNA, cells were transfected with Bcl-xL,
XIAP, or FAIM-L overexpression plasmids (Fig. 3A). After 2 d of
transfection, cells were treated with sFasL in combination with
AD for 24 h. Right before treatment, efficiency of XIAP (Fig. 3C)
and FAIM-L knockdown (Fig. 3D) was checked. As shown in
Figure 3A and in accordance with results of Figures 1A and 2C,
overexpression of Bcl-xL, XIAP, and FAIM-L protected Scrambled-
transduced PC12 cells from sFasL and AD treatment. However,
after XIAP knockdown using two different shRNA, only Bcl-xL
but not FAIM-L overexpression was able to significantly protect
cells from apoptosis. Interestingly, the protection exerted by
Bcl-xL overexpression after XIAP silencing demonstrates that the
knockdown of XIAP does not shift PC12 cells from Type II to
Type I cells. These data support that, at least in our model, XIAP
levels rather than mitochondrial implication is the critical factor
for the protective function of FAIM-L. On the other hand, we
investigated whether the endogenous levels of FAIM-L were re-
quired for the antiapoptotic role of XIAP using the same ap-
proach as in Figure 3A. As shown in Figure 3B, both XIAP and
Bcl-xL overexpression is able to rescue PC12 cells that have been
transduced with FAIM-L shRNA-carrying lentiviral particles and
treated with sFasL and AD. Notably, the knockdown of either
XIAP (Fig. 3A) or FAIM-L (Fig. 3B) sensitizes PC12 cells to the
sole treatment with sFasL (compared with ScrpcDNA3 con-
ditions treated with sFasL). Together, we conclude that high
intracellular levels of XIAP following overexpression render
endogenous FAIM-L dispensable for XIAP to exert its protective
role. However, endogenous XIAP is required for the antiapop-
totic function of FAIM-L. These results were further reproduced
in primary neuronal cultures. Ectopic expression of Bcl-xL and
FAIM-L was able to protect primary cortical neurons against
FasL-induced apoptosis, thereby indicating that cortical neurons
behave as Type II cells. However, after XIAP knockdown, Bcl-xL
but not FAIM-L overexpression was able to protect from FasL-
induced apoptosis (Fig. 3E).
The interaction of FAIM-L with XIAP is required for its
antiapoptotic function
We sought to determine whether XIAP is a molecular partner of
FAIM-L. Semi-endogenous (Fig. 4A) and endogenous immuno-
precipitation experiments (Fig. 4B) were performed by immuno-
precipitation of endogenous FAIM-L, using an antibody raised
against the 22 amino acid sequence specific of FAIM-L (Segura et
al., 2007), followed by immunoblotting of transfected 6xMyc-
tagged XIAP (Fig. 4A) or endogenous XIAP (Fig. 4B). Both ap-
proaches demonstrate that endogenous FAIM-L is able to
interact with XIAP. In the nervous system, FAIM-L protects from
DR-induced apoptosis while its shorter isoform FAIM-S fails to
protect from FasL and TNF-induced apoptosis. Even though
the physiological roles of both isoforms are different in the ner-
vous system, their protein sequences only differ by the presence
of 22 additional amino acids at the N terminus of FAIM-L (Fig.
4E). Moreover, secondary structure prediction algorithms of the
FAIM-L-specific sequence do not reveal the existence of any par-
ticular domain. HEK293T cells were transfected with FLAG-
tagged XIAP in combination with nontagged FAIM-L or
FAIM-S. We performed XIAP immunoprecipitation followed by
immunoblotting using, first, the anti-FAIM-L and then the anti-
FAIM antibody, which is raised against the full-length protein,
therefore detecting both isoforms. Comparison of results ob-
tained with both antibodies clearly demonstrates that XIAP in-
teracts with FAIM-L but not FAIM-S (Fig. 4C). This finding
allows us to map the interaction of XIAP with the N-terminus
of FAIM-L. Interestingly, since XIAP is a functional target
of FAIM-L, the specific interaction of XIAPwith FAIM-L but not
FAIM-S might give a clue about the mechanism of protection of
FAIM-L. IAP antagonists, such as Smac/Diablo, Omi/HtrA2,
Grim, Hid, Reaper, and processed caspase-9, but also the more
recently reported Nsp4 and CLPX (Verhagen et al., 2007), inter-
act with the BIR domains of IAPs through an exposedN-terminal
so-called IAP-BindingMotif (IBM) starting with an alanine. The
protein sequence of mature FAIM-L starts with an alanine (Fig.
4D), which we mutated to a glycine residue to determine whether
this N-terminal amino acid is required for the interaction of
FAIM-LwithXIAP (Fig. 4E). Consistentwith our hypothesis, this
mutation eliminated the interaction of FAIM-L with XIAP (Fig.
4F). HEK293T cells were transfected with FLAG-tagged XIAP
together with nontaggedwt FAIM-L ormut FAIM-L. After FLAG
immunoprecipitation followed by immunoblotting using the
anti-FAIM antibody, we show that the interaction of XIAP with
FAIM-L is lost when the IBM of FAIM-L is mutated. Finally, to
demonstrate that the interaction of XIAP and FAIM-L is relevant
for the antiapoptotic function of FAIM-L, PC12 cells were trans-
fected with wt FAIM-L or mut FAIM-L, then treated with sFasL
and AD for 24 h. As shown in Figure 4G, themutation of the IBM
of FAIM-L abrogates its protective effect. These results indicate
that FAIM-L directly interacts with XIAP through its IBM and
further support the notion that XIAP endogenous levels as well as
its interaction with FAIM-L are essential for the anti-apoptotic
function of FAIM-L.
FAIM-L interacts with XIAP through its BIR2 domain
To determine the FAIM-L-binding domain of XIAP, we pro-
ceeded to coimmunoprecipitate FAIM-L with the different XIAP
deletion or point mutants that are schematically represented in
Figure 5A. Figure 5B shows that the interaction of FAIM-L with
the BIR2 domain is very strong, and the presence of the BIR2
domain is critical for the interaction of the XIAP deletion mu-
tants with FAIM-L. Indeed, FAIM-L was found to interact with
XIAP fragments, including the BIR2 domain (lanes 2, 4, 6, 7, and
8) but does not interact with either BIR1 or BIR3 domains (lanes
3 and 5) (Fig. 5B). Because studies using BIR domains of XIAP
that might disrupt the protein structure and folding have to be
cautiously interpreted, we intended to verify these results using
XIAP constructs with BIR domains that bear mutations in resi-
dues essential for XIAP antiapoptotic function. The XIAP D214S
mutant interferes with XIAP binding to its antagonist Smac,
whereas the XIAP E314S mutant interferes with both Smac and
processed caspase-9 binding (Silke et al., 2002). As shown in Fig-
ure 5C, FAIM-L retains interaction with the BIR3 domain mu-
tant of XIAP (E314S), whereas this interaction is eliminated by
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the mutation of the BIR2 domain (D214S) or the double muta-
tion (D214SE314S). These results further support our findings
that the BIR2 domain is necessary for the interaction of XIAP
with FAIM-L. To inquire whether FAIM-L might interfere with
the interaction of XIAP with its antagonist Smac, PC12 cells were
transfected with full-length XIAP and XIAP point mutants, with
or without the 3xHA-FAIM-L encoding plasmid (Fig. 5D). The
interaction of XIAP with endogenous Smac is slightly reduced by
the XIAP D214S mutant but impaired by the XIAP E314S and
XIAPD214SE314Smutants (Fig. 5D, lanes 1–5), supporting pre-
vious observations of Smac interaction with the BIR3 domain of
XIAP (Riedl and Shi, 2004). The overexpression of FAIM-L does
not displace the interaction of XIAP with Smac (Fig. 5D, lanes
6–10), suggesting that FAIM-L acts independently of Smac inter-
action with XIAP and rather performs a direct action on XIAP,
even though the cellular machinery is prompt to kill.
FAIM-Lmaintains XIAP stability through inhibition of
auto-ubiquitinylation and degradation
Since endogenous levels of XIAP are critical for FAIM-L to pro-
tect from apoptosis, and XIAP is subject to auto-ubiquitinylation
due to the E3-ligase property of its RING domain (Yang et al.,
2000), we sought to determine whether FAIM-L affects XIAP
auto-ubiquitinylation. First, HEK293T cells were transfected
with the 6xHis-Ubiquitin-encoding plasmid together with the
6xMyc-XIAP or 6xMyc XIAP H467Amutant that abrogates its
E3-ligase function. After ubiquitin pulldown, the auto-
ubiquitinylation of XIAP is evident by immunoblotting with
XIAP antibody (Fig. 6A). TheXIAPH467Amutant lost this ubiq-
uitinylation pattern (Fig. 6A). This result validates a ubiquitin
pull-down protocol, which specifically detects XIAP auto-
ubiquitinylation pattern. Subsequently, we sought to determine
whether FAIM-L affects XIAP auto-ubiquitinylation (Fig. 6B).
Interestingly, FAIM-L overexpression completely abrogates
XIAP auto-ubiquitinylation (Fig. 6B, lane 4). To corroborate that
XIAP ubiquitinylation leads to its degradation by the protea-
some, cells transfected as in lanes 1–4 were treated with the pro-
teasome inhibitor MG132 for 6 h before harvesting (lanes 5–8).
As seen in Figure 6B, the strong ubiquitinylation pattern in lane 6
reveals that XIAP auto-ubiquitinylation is degradative. Lysates
were immunoblotted against all transfected proteins as well as
Mcl-1, to control that the lack of XIAP auto-ubiquitinylation in
the presence of FAIM-L is not due to a defective proteasome.
Indeed, Mcl-1 protein levels significantly increased in cells
treated with MG132 compared with vehicle (Fig. 6B, lanes 5–8).
We next proceeded to determine whether the inhibition of XIAP
auto-ubiquitinylation and degradation by FAIM-L effectively
stabilized XIAP levels. PC12 cells were transfected with 3xFLAG-
FAIM-L encoding plasmid or empty vector (pcDNA3) and
treated with actinomycin D for several days. Whereas XIAP pro-
tein levels drop between 2 and 4 d of AD treatment, FAIM-L
overexpression maintains stable levels of endogenous XIAP (Fig.
6C). To further demonstrate that FAIM-L affects XIAP stability
in primary neurons, we performed FAIM-L knockdown in corti-
cal neurons and checked XIAP levels after several days in vitro. As
seen in Figure 6D, XIAP levels drastically drop in the absence of
FAIM-L. We next sought to determine whether FAIM-L knock-
down, apart from resulting in XIAP ubiquitinylation and degra-
dation, is able to induce a more rapid degradation of XIAP upon
FasL treatment. Cortical neurons transduced with Scrambled or
shFAIM-L lentiviral particles for 4 d were treated with sFasL for
24 h. As seen in Figure 3B for PC12 cells, the sole treatment of
cortical neurons with sFasL induces apoptosis after FAIM-L
knockdown (27.31% of apoptosis, data not shown). However,
even though XIAP stability is slightly decreased in neurons after
4 d of shFAIM-L transduction, the treatment with sFasL for 24 h
induced apoptosis without affecting any further XIAP stability
(Fig. 6E). In conclusion, we report that, in Type II cells, FAIM-L
overexpression reduces XIAP auto-ubiquitinylation and en-
hances its stability, leading to cell survival after Fas stimulation
(Fig. 6F). Our results uncover the role of XIAP as a critical part-
ner of a death receptor antagonist and shed new light on the
unknown mechanism of protection of FAIM-L.
Discussion
Mature neurons are postmitotic cells that should survive for the
lifetime of an organism, and pathological situations, such as neu-
rodegenerative diseases, remain a major clinical challenge. The
emergence of FAIM-L as an antiapoptotic protein that is specifi-
cally expressed in neurons may provide an important avenue for
the conception of novel therapies. However, even though we and
others have reported the function of FAIM-L in neuronal protec-
tion from DR-induced apoptosis (Segura et al., 2007; Yu et al.,
2008), the understanding of its mechanism of action is still lack-
ing. Our work puts in evidence the mechanism of action of
FAIM-L by pointing out at XIAP as its critical partner for protec-
tion from FasL-induced apoptosis.
The Fas/FasL system limits inflammatory and immune re-
sponse in the CNS. Although basal expression of Fas/FasL is low,
its activation in various neurological disorders causes neuronal
damage. The Fas/FasL pathway has roles both in maintaining the
immune-suppressed status of the CNS and in inducing neuronal
death in Alzheimer’s disease (Morishima et al., 2001), Hunting-
ton’s disease (Ferrer et al., 2000), and Parkinson’s disease (Mogi
et al., 1996; Ferrer et al., 2000), as well as amyotrophic lateral
sclerosis (Raoul et al., 2002). In the present article, we show that
FAIM-L protects neuronal Type II and not Type I cells from
Fas-induced apoptosis. It is generally accepted that protection
from FasL-induced apoptosis by the antiapoptotic Bcl-2 family
members (e.g., Bcl-2, Bcl-xL) determines a certain cell type as
“Type II.” Alternatively, protection against FasL-induced apop-
tosis due to loss of function of proapoptoticmembers of the Bcl-2
family (e.g., Bax, Bak) can also classify cells as “Type II.” In this
sense, several studies performed in the nervous system have
shown the relevance of antiapoptotic Bcl-2 family members in
DR-induced apoptosis (Benn and Woolf, 2004).
In accordance with previous results (Jost et al., 2009), we
found XIAP upregulated in Type II and downregulated in Type I
cells after stimulation of the Fas receptor. Most importantly, we
4
(Figure legend continued.) counterpart. *p0.01.B, PC12 cellswere transducedas inAwith
Scrambled shRNA (Scr) or shRNA FAIM-L lentiviral particles and then transfected with pcDNA3,
3xHA-Bcl-xL, or 6xMyc-XIAP and treated as in A. Conditions of Scrambled-transduced cells are
identical in A and B. Percentage of apoptosis was assessed and Student test was performed,
comparing Bcl-xL, XIAP, and FAIM-L-overexpressing cells treated with sFasLAD with their
control (pcDNA3)-treated counterpart. **p0.001. *p0.01.C, RT-PCRusing rat XIAPor L27
primers was performed to control XIAP knock-down efficiency. D, Immunoblot analysis fol-
lowed by Naphtol Blue staining of the PVDF membrane confirmed FAIM-L knockdown effi-
ciency. E, Cortical neurons were transduced with Scrambled shRNA (Scr) or shRNA XIAP R1
lentiviral particles for 3 d and then transduced with empty, Bcl-xL, or FAIM-L overexpression
lentiviral particles for 3 additional days. Primary neurons were treated with sFasL (100 ng/ml)
and cycloheximide (CHX; 1g/ml) for 24 h. Percentage of apoptosis was assessed and Student
test was performed, comparing Bcl-xL and FAIM-L-overexpressing neurons treated with
sFasLCHX with their control (Empty)-treated counterpart. *p 0.01. All conditions repre-
sent the mean of three independent experiments.
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provide strong evidence that endogenous levels of XIAP are crit-
ical for the antiapoptotic function of FAIM-L because FAIM-L
can no longer protect neuron-like cells and cortical neurons from
Fas-induced apoptosis after XIAP knockdown. We have previ-
ously demonstrated that FAIM-L interacts with the Fas receptor
and competes with the interaction of Fas with its adaptor FADD
(Segura et al., 2007). Intriguingly, we found here that FAIM-L
also acts downstreamof Bax activation and release of cytochrome
c and Smac from the mitochondria. These data point to a dual
role of FAIM-L in the apoptotic cascade: one at the DISC level
and another downstream of the mitochondria. Indeed, although
FAIM-L is able to coimmunoprecipitate with both the Fas recep-
tor and XIAP, XIAP is only able to interact with FAIM-L and not
with Fas (data not shown). Also, we observe a cytosolic intracel-
lular distribution of FAIM-L rather than an expression pattern
that is restricted to the plasma membrane (Segura et al., 2007).
We therefore speculate that FAIM-L interacts with the Fas recep-
tor to impede the recruitment of FADD and then directly with
XIAP at the postmitochondrial level. We report the existence of
an IBM in the amino terminus of FAIM-L, which is necessary for
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its interactionwith the BIR2 domain of XIAP and therefore for its
antiapoptotic function. These findings underline the relevance of
the interaction between FAIM-L and XIAP that both protect
from Fas-induced apoptosis downstream Bax activation. Finally,
we demonstrate that FAIM-L stabilizes XIAP through the inhibi-
tion of its auto-ubiquitinylation and degradation by the protea-
some, therefore preventing cell death.
Huo et al. (2009) engineered Faim knock-out mice that were
viable, even though B cells and thymocytes of mutant mice
showed increased sensitivity to Fas-induced apoptosis and exac-
erbated liver damage in response to Fas engagement in vivo. The
authors also report, in accordance with our previous results, a
regulation of the physical binding of caspase-8 to the Fas receptor
in thymocytes.Xiap knock-outmice are viable, and a redundancy
with other members of the IAP family has been observed. Xiap-
null thymocytes, splenocytes, and embryonic fibroblasts die nor-
mally in response to different apoptotic stimuli (Harlin et al.,
2001). However, two types of postmitotic cells from Xiap-null
mice (i.e., sympathetic neurons, Potts et al., 2003; and cardiomy-
ocytes, Potts et al., 2005) rapidly die after microinjection of cyto-
chrome c, whereas wild-type cells remain insensitive. Xiap-null
mice have an exacerbated response to perinatal hypoxia-ischemia
that leads to neuronal apoptosis and tissue loss (West et al., 2009).
These observations support that, at least in mitotic cells, XIAP is
a critical regulator of apoptosis. Also, apoptosis after nerve
growth factor deprivation in cultured sympathetic neurons re-
quire XIAP inhibition (Potts et al., 2003). Similarly, motoneu-
rons and neuronally differentiated PC12 pheochromocytoma
cells require inhibition of XIAP to die after axotomy and growth
factor withdrawal, respectively (Perrelet et al., 2004; Vyas et al.,
2004). XIAP levels deregulation has been shown extensively in
peripheral nervous system-related diseases and has been pro-
posed as a therapeutic strategy (Garrity-Moses et al., 2006). For
example, XIAP levels have been found decreased after motoneu-
ron axotomy (Perrelet et al., 2002) and in mouse models of fa-
milial amyotrophic lateral sclerosis (Ishigaki et al., 2002).
Moreover, XIAP levels have also been found reduced inHunting-
ton’s disease (Goffredo et al., 2005) and Alzheimer’s disease
(Tanaka et al., 2006). Immunohistochemical studies suggest that
XIAP may be partially associated with the pathogenesis of Par-
kinson’s disease and dementia with Lewy bodies (Kawamoto
et al., 2012). Interestingly, XIAP dysfunction resulting from
S-nitrosylation has also been described in Parkinson’s disease
(Tsang et al., 2009). Also, transgenic expression of XIAP in neu-
rons using the neuron-specific enolase promoter (nse-XIAP) im-
proves prognosis in a mouse model of Parkinson’s disease
(Crocker et al., 2003).More recently, it has been shown that XIAP
is able to regulate the activation of caspase-3 that allows axonal
degeneration in sensory neurons from DRG after trophic factor
deprivation. Moreover, XIAP/mice embryos show decreased
skin innervation. These data show the relevance of XIAP on the
physiological regulation of caspase-3 and have important conse-
quences for the shaping of the nervous system during development
(Unsain et al., 2013). Our results suggest that FAIM-L could have
potential physiological functions, apart from regulating neuronal
death through death receptors. Further studies are required to dem-
onstrate the involvement of FAIM-L in such a paradigm.
These reports are in line with our findings that XIAP regula-
tion by FAIM-L, which inhibits XIAP auto-ubiquitinylation and
degradation, is critical for the cell decision between death and
survival. A growing body of evidence supports that the E3 ubiq-
uitin ligase activity of XIAP plays a key role in its participation to
cellular signaling cascades (Galba´n and Duckett, 2010). Schile et
al. (2008) investigated the E3 ubiquitin ligase activity of XIAP
through the inactivation of the RING motif by gene targeting.
Deleting the RING domain stabilized XIAP in apoptotic thymo-
cytes, demonstrating that XIAP E3 ubiquitin ligase activity is
a major determinant for its stability. These findings correlate
with our results showing that the inhibition of XIAP auto-
ubiquitinylation by FAIM-L is sufficient for XIAP stability. More
recently, Damgaard et al. (2012) reported that the RING domain
of XIAP is essential for NOD2 signaling through the XIAP-
mediated ubiquitinylation of RIPK2 and the recruitment of the
linear ubiquitin chain assembly complex toNOD2. Our findings,
that FAIM-L is an IAP-binding protein that, unlike the antago-
nists Smac/DIABLO and HtrA2/Omi, serves as an XIAP “guard-
ian,” highlight the potential use of FAIM-L as a therapeutic tool
for neuronal protection in neurodegenerative diseases.
It is still unknown whether XIAP and/or FAIM-null mice are
prone to neurodegenerative diseases. Many neurodegenerative
diseases have a strong apoptotic component, and blocking apo-
ptosis could have therapeutic benefits. Therefore, the inhibition
of IAP degradationmight constitute a powerful pharmacological
target in neurodegenerative disease. Our results bring strong ev-
idence for the role of FAIM-L in maintaining XIAP endogenous
levels and protecting cells from apoptosis. In this sense, it would
be interesting to determine whether a neuron-specific molecule,
such as FAIM-L, which is a “guardian” of XIAP, might play a
physiological role in preventing cell death upon caspase-3 activa-
tion. Ourmechanistic work brings great insight into the potential
use of FAIM-L as a therapeutic tool for neuronal protection from
caspase activation.
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